Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 29;31(1):229-249.
doi: 10.3390/curroncol31010015.

Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer

Jacek Wilczyński  1 , Edyta Paradowska  2 , Justyna Wilczyńska  3 , Miłosz Wilczyński  4   5
Affiliations
Review

Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer

Jacek Wilczyński et al. Curr Oncol. .

Abstract

High-grade serous ovarian cancer (HGSOC) is one of the most lethal tumors generally and the most fatal cancer of the female genital tract. The approved standard therapy consists of surgical cytoreduction and platinum/taxane-based chemotherapy, and of targeted therapy in selected patients. The main therapeutic problem is chemoresistance of recurrent and metastatic HGSOC tumors which results in low survival in the group of FIGO III/IV. Therefore, the prediction and monitoring of chemoresistance seems to be of utmost importance for the improvement of HGSOC management. This type of cancer has genetic heterogeneity with several subtypes being characterized by diverse gene signatures and disturbed peculiar epigenetic regulation. HGSOC develops and metastasizes preferentially in the specific intraperitoneal environment composed mainly of fibroblasts, adipocytes, and immune cells. Different HGSOC subtypes could be sensitive to distinct sets of drugs. Moreover, primary, metastatic, and recurrent tumors are characterized by an individual biology, and thus diverse drug responsibility. Without a precise identification of the tumor and its microenvironment, effective treatment seems to be elusive. This paper reviews tumor-derived genomic, mutational, cellular, and epigenetic biomarkers of HGSOC drug resistance, as well as tumor microenvironment-derived biomarkers of chemoresistance, and discusses their possible use in the novel complex approach to ovarian cancer therapy and monitoring.

Keywords: biomarkers; chemoresistance; ovarian cancer; prediction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ovarian Cancer Survival Rates|Ovarian Cancer Prognosis|American Cancer Society. [(accessed on 11 December 2023)]. Available online: https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-s....
    1. Ray-Coquard I., Leary A., Pignata S., Cropet C., González-Martín A., Marth C., Nagao S., Vergote I., Colombo N., Mäenpää J., et al. Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer: Final Overall Survival Results from the PAOLA-1/ENGOT-Ov25 Trial. Ann. Oncol. 2023;34:681–692. doi: 10.1016/j.annonc.2023.05.005. - DOI - PubMed
    1. Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., Sorio R., Vergote I., Witteveen P., Bamias A., et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. JCO. 2014;32:1302–1308. doi: 10.1200/JCO.2013.51.4489. - DOI - PubMed
    1. Aghajanian C., Blank S.V., Goff B.A., Judson P.L., Teneriello M.G., Husain A., Sovak M.A., Yi J., Nycum L.R. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. JCO. 2012;30:2039–2045. doi: 10.1200/JCO.2012.42.0505. - DOI - PMC - PubMed
    1. Oza A.M., Cook A.D., Pfisterer J., Embleton A., Ledermann J.A., Pujade-Lauraine E., Kristensen G., Carey M.S., Beale P., Cervantes A., et al. Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial. Lancet Oncol. 2015;16:928–936. doi: 10.1016/S1470-2045(15)00086-8. - DOI - PMC - PubMed

Publication types